| Followers | 96 |
| Posts | 5080 |
| Boards Moderated | 0 |
| Alias Born | 02/07/2021 |
Tuesday, October 11, 2022 2:49:18 PM
Ad hominem attacks on 5/9 placed before data release on 5/10 were an attempt to poison the well meaning turn those who recently bought NWBO against the firm. Adam Feuerstein tried to drive a wedge between UCLA and Northwest Biotherapeutics by claiming Linda Liau was not able to attend NYAS due to trial failure.
He was successful. To the new uninformed retail shareholder, who saw this blue checkmark journalist from Statnews making inflammatory statements, the doubt had a material impact. Combine that with stop losses the event decimated the intraday market cap of Northwest Biotherapeutics before the NYAS presentation even began. This timeline isn't in dispute.
Management cannot stop a muckracking "journalist" from making potentially libelous statements nor can the government. The Supreme Court has roundly rejected prior restraint. The burden now exists on management to prove this criminal manipulation did in fact occur. I believe they have evidence in place though their primary focus remains approval for DCVax. As we know from MHRA they remain very close.
He was successful. To the new uninformed retail shareholder, who saw this blue checkmark journalist from Statnews making inflammatory statements, the doubt had a material impact. Combine that with stop losses the event decimated the intraday market cap of Northwest Biotherapeutics before the NYAS presentation even began. This timeline isn't in dispute.
Management cannot stop a muckracking "journalist" from making potentially libelous statements nor can the government. The Supreme Court has roundly rejected prior restraint. The burden now exists on management to prove this criminal manipulation did in fact occur. I believe they have evidence in place though their primary focus remains approval for DCVax. As we know from MHRA they remain very close.
"Big opportunities come infrequently. When it's raining gold, reach for a bucket, not a thimble - Warren Buffett."
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
